Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The primary purpose of this study is to obtain long-term safety data with CZP in patients with Rheumatoid Arthritis (RA). Additional objectives are to assess the dose and type of Arthritis medication(s) utilized by patients, and to assess the long-term impact of CZP on physical function. Treatment will continue up to approval of a marketing application for this product.
| Condition | Intervention | Phase |
|---|---|---|
|
Rheumatoid Arthritis |
Biological: Certolizumab Pegol |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase III, Multicenter, Open-Label Long-Term Study to Assess the Safety and Tolerability of CDP870 400 mg Subcutaneously Every 4 Weeks, in Subjects With Rheumatoid Arthritis |
- Percentage of Subjects With at Least One Adverse Event (AE) During the Study Period of 8 Years [ Time Frame: From first dose of CZP up to 8 years ] [ Designated as safety issue: No ]
An AE is any untoward medical occurrence in a subject or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.
First dose of CZP was at Baseline of one of the feeder studies C87011 [NCT00548834] or C87014 [NCT00544154] for subjects randomized to CZP, or at First Visit (Week 0) of this study for subjects randomized to Placebo.
- Percentage of Subjects Who Withdrew Due to an Adverse Event (AE) During the Study Period of 8 Years [ Time Frame: From First Visit (Week 0 in this study) up to 8 years ] [ Designated as safety issue: No ]
An AE is any untoward medical occurrence in a subject or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.
The results of this Primary Outcome Measure are summarized from the Adverse Event pages of the Case Report Forms.
- Percentage of Subjects Meeting the American College of Rheumatology 20% Response Criteria (ACR20) at Week 52 [ Time Frame: From Baseline to Week 52 ] [ Designated as safety issue: No ]
The assessments are based on a 20% or greater improvement from Baseline to Week 52 in the number of tender joints, a 20% or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
Baseline is Baseline of the respective feeder study.
- Percentage of Subjects Meeting the American College of Rheumatology 20% Response Criteria (ACR20) at Week 100 [ Time Frame: From Baseline to Week 100 ] [ Designated as safety issue: No ]
The assessments are based on a 20% or greater improvement from Baseline to Week 100 in the number of tender joints, a 20% or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
Baseline is Baseline of the respective feeder study.
- Percentage of Subjects Meeting the American College of Rheumatology 20% Response Criteria (ACR20) at Week 160 [ Time Frame: From Baseline to Week 160 ] [ Designated as safety issue: No ]
The assessments are based on a 20% or greater improvement from Baseline to Week 160 in the number of tender joints, a 20% or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
Baseline is Baseline of the respective feeder study.
- Percentage of Subjects Meeting the American College of Rheumatology 20% Response Criteria (ACR20) at Week 208 [ Time Frame: From Baseline to Week 208 ] [ Designated as safety issue: No ]
The assessments are based on a 20% or greater improvement from Baseline to Week 208 in the number of tender joints, a 20% or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
Baseline is Baseline of the respective feeder study.
- Percentage of Subjects Meeting the American College of Rheumatology 20% Response Criteria (ACR20) at Week 256 [ Time Frame: From Baseline to Week 256 ] [ Designated as safety issue: No ]
The assessments are based on a 20% or greater improvement from Baseline to Week 256 in the number of tender joints, a 20% or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
Baseline is Baseline of the respective feeder study.
- Percentage of Subjects Meeting the American College of Rheumatology 20% Response Criteria (ACR20) at Week 316 [ Time Frame: From Baseline to Week 316 ] [ Designated as safety issue: No ]
The assessments are based on a 20% or greater improvement from Baseline to Week 316 in the number of tender joints, a 20% or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
Baseline is Baseline of the respective feeder study.
- Percentage of Subjects Meeting the American College of Rheumatology 20% Response Criteria (ACR20) at Completion Visit or Early Withdrawal Visit [ Time Frame: From Baseline to Completion Visit/ early Withdrawal Visit, up to 8 years ] [ Designated as safety issue: No ]The assessments are based on a 20% or greater improvement from Baseline to the Completion Visit or early Withdrawal Visit in the number of tender joints, a 20% or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
- Percentage of Subjects Meeting the American College of Rheumatology 50% Response Criteria (ACR50) at Completion Visit or Early Withdrawal Visit [ Time Frame: From Baseline to Completion Visit/ early Withdrawal Visit, up to 8 years ] [ Designated as safety issue: No ]The assessments are based on a 50% or greater improvement from Baseline to the Completion Visit or early Withdrawal Visit in the number of tender joints, a 50% or more improvement in the number of swollen joints, and a 50% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
- Percentage of Subjects Meeting the American College of Rheumatology 70% Response Criteria (ACR70) at Completion Visit or Early Withdrawal Visit [ Time Frame: From Baseline to Completion Visit/ early Withdrawal Visit, up to 8 years ] [ Designated as safety issue: No ]The assessments are based on a 70% or greater improvement from Baseline to the Completion Visit or early Withdrawal Visit in the number of tender joints, a 70% or more improvement in the number of swollen joints, and a 70% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
- Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ- DI) at Completion Visit or Early Withdrawal Visit [ Time Frame: From Baseline to Completion Visit/ early Withdrawal Visit, up to 8 years ] [ Designated as safety issue: No ]The HAQ-DI assesses the degree of difficulty experienced in eight domains (Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Gripping, Other Activities) of daily living activities using 20 questions. The HAQ-DI is calculated by summing the domain scores and dividing them by the number of domains. It ranges from 0 (no difficulty) to 3 (unable to do). Negative values indicate an improvement from Baseline to the Post-Baseline Visit with larger negative values showing a better improvement.
- Percentage of Subjects Who Withdrew Due to Lack of Efficacy During the Study Period of 8 Years [ Time Frame: From First Visit (Week 0 in this study) up to 8 years ] [ Designated as safety issue: No ]
- Percentage of Subjects Utilizing Common Additional Arthritis Medications During the Study Period of 8 Years [ Time Frame: From First Visit (Week 0 in this study) up to 8 years ] [ Designated as safety issue: No ]This Secondary Outcome Measure shows additional arthritis medications received by at least 20% of subjects during the 8-year study.
| Enrollment: | 402 |
| Study Start Date: | March 2003 |
| Study Completion Date: | February 2011 |
| Primary Completion Date: | February 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Certolizumab Pegol |
Biological: Certolizumab Pegol
400 mg of Certolizumab Pegol subcutaneously every 4 Weeks
Other Name: Cimzia
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participation in CZP trial C87014 or C87011
- If female and of childbearing potential, she agrees to participate in this study by providing written informed consent, has been using adequate contraception since her last menses, will use adequate contraception during the study and for 12 weeks after the last dose of study drug (or longer if required by local regulations), is not lactating, and has had a negative urine pregnancy test on the day of receiving the first dose of study drug
- Must have provided written informed consent before undergoing any study procedures
Exclusion Criteria:
- History (Hx) of chronic infection, serious or life-threatening infection - (including Herpes Zoster) within 6 months prior, or any current symptom indicating infection
- Current or recent Hx of severe, progressive and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological or cerebral disease
- Any finding indicative of Tuberculosis at end of previous study
- Known HIV infection
- Persistently abnormal AST (Aspartate Aminotransferase) or ALT (Alanine Aminotransferase) results (> 2 times upper limit of normal)
- Hemoglobin (Hgb) levels < 9 g/dL or Hematocrit < 30 %
- Total White Blood Cell (WBC) count of < 3.0 x 100/L (< 3000/mm^3)
- Platelet count < 100 x 100 L (100,000/mm^3)
- Serum creatinine > 1.5 times upper limit of normal based on patient age and sex
- Receipt of any biological therapies for RA in 6 months prior to study entry or any prior treatment (tx) with Tumor Necrosis Factor (TNF) blocking agent (excluding CDP870)
- Receipt of any vaccination (live, attenuated or killed) in 8 weeks prior to Baseline
- Any other condition which the Principal Investigator judges would make patient unsuitable for study participation
Contacts and Locations
Hide Study Locations| United States, Alabama | |
| Huntsville, Alabama, United States | |
| United States, Arizona | |
| Paradise Valley, Arizona, United States | |
| United States, District of Columbia | |
| Washington, District of Columbia, United States | |
| United States, Florida | |
| Aventura, Florida, United States | |
| Clearwater, Florida, United States | |
| Ocala, Florida, United States | |
| Orlando, Florida, United States | |
| Tampa, Florida, United States | |
| United States, Idaho | |
| Coeur d'Alene, Idaho, United States | |
| United States, Illinois | |
| Springfield, Illinois, United States | |
| United States, Kansas | |
| Wichita, Kansas, United States | |
| United States, Maryland | |
| Wheaton, Maryland, United States | |
| United States, Massachusetts | |
| Fall River, Massachusetts, United States | |
| United States, Missouri | |
| St. Louis, Missouri, United States | |
| United States, Nebraska | |
| LIncoln, Nebraska, United States | |
| United States, North Carolina | |
| Charlotte, North Carolina, United States | |
| United States, Ohio | |
| Cleveland, Ohio, United States | |
| Dayton, Ohio, United States | |
| United States, Pennsylvania | |
| Erie, Pennsylvania, United States | |
| West Reading, Pennsylvania, United States | |
| United States, South Carolina | |
| Charleston, South Carolina, United States | |
| United States, Tennessee | |
| Memphis, Tennessee, United States | |
| United States, Texas | |
| Austin, Texas, United States | |
| Dallas, Texas, United States | |
| Duncansville, Texas, United States | |
| Lubbock, Texas, United States | |
| San Antonio, Texas, United States | |
| San Diego, Texas, United States | |
| United States, Washington | |
| Everett, Washington, United States | |
| Austria | |
| Graz, Austria | |
| Klagenfurt, Austria | |
| Vienna, Austria | |
| Belgium | |
| Antwerpen, Belgium | |
| Diepenbeek, Belgium | |
| Liege, Belgium | |
| Merksem, Belgium | |
| Czech Republic | |
| Ceske Budejovice, Czech Republic | |
| Liberec, Czech Republic | |
| Ostrava Trebovice, Czech Republic | |
| Prague 2, Czech Republic | |
| Praha4 -krc, Czech Republic | |
| Uherske Hradiste, Czech Republic | |
| Germany | |
| Berlin, Germany | |
| Gortlitz, Germany | |
| Hamburg, Germany | |
| Jena, Germany | |
| Koln, Germany | |
| Leipzig, Germany | |
| Ratingen, Germany | |
| Ireland | |
| Dublin, Ireland | |
| Waterford, Ireland | |
| United Kingdom | |
| Birmingham, United Kingdom | |
| Cannock, United Kingdom | |
| Colchester, United Kingdom | |
| Glasgow, United Kingdom | |
| Harrogate, United Kingdom | |
| London, United Kingdom | |
| Manchester, United Kingdom | |
| Oxford, United Kingdom | |
| Peterborough, United Kingdom | |
| Wirral, United Kingdom | |
| Study Director: | UCB Clinical Trial Call Center | +1 877 822 9493 (UCB) |
More Information
Additional Information:
No publications provided
| Responsible Party: | UCB, Inc. |
| ClinicalTrials.gov Identifier: | NCT00160693 History of Changes |
| Other Study ID Numbers: | C87015, 2005-002617-21 |
| Study First Received: | September 6, 2005 |
| Results First Received: | February 15, 2012 |
| Last Updated: | June 4, 2012 |
| Health Authority: | Austria: Federal Ministry for Health and Women Belgium: Directorate general for the protection of Public health: Medicines Czech Republic: State Institute for Drug Control Germany: Paul-Ehrlich-Institut Ireland: Irish Medicines Board United Kingdom: Medicines and Healthcare Products Regulatory Agency United States: Food and Drug Administration |
Keywords provided by UCB, Inc.:
|
Rheumatoid Arthritis America College of Rheumatology Disease modifying anti-rheumatic drug Certolizumab Pegol (CDP870) |
Additional relevant MeSH terms:
|
Arthritis Arthritis, Rheumatoid Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases |
Immune System Diseases Antirheumatic Agents Immunoglobulin Fab Fragments Therapeutic Uses Pharmacologic Actions Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 19, 2013